Clinical Evaluation of Vaginal Suture Knotting Device in the Treatment of Urinary Incontinence in Women
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 67
- Locations
- 4
- Primary Endpoint
- Urodynamic Assessment
Study Overview
Brief Summary
Stress Urinary incontinence (SUI) is a common health condition in the female population. Mid-urethral slings (MUS) have proven to be effective in the treatment of female SUI. Trans-obturator tape (TOT) has been demonstrated to be as effective as retropubic tension-free vaginal tape (TVT) with fewer major complications. In this study, it is aimed to evaluate the effectiveness and safety of a newly developed, innovative medical device, as compared to TOT, in the patients diagnosed with urinary incontinence and requiring the surgical intervention.
Detailed Description
The study is an open-label, prospective, parallel-group, randomized, controlled medical device clinical trial, conducted in two centers. The two arms of the trial consist of patients randomized to the new device group and to the TOT group. According to this distribution, one group will be subjected to the operation with the new device, and the other group will be subjected to the operation with a commercially available TOT. Primary objective: Evaluation of the effectiveness of using the new device in the surgical treatment of urinary incontinence. Secondary objectives: Evaluation of the effects of the new device use on patients' quality of life, treatment satisfaction, and sexual functions, as well as assessment of safety. The study includes evaluation of the progress employing objective (pad weight, number of incontinence episodes, urodynamic tests) and subjective tests (questionnaires, diaries) during the 12 months follow-up period.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 40 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Those who have not received radiotherapy
- •Women aged 40-65 years
- •Accompanying infection according to urine culture results people who do not
- •Informed about the study and participated in the study patients who have agreed to participate
- •Acceptable contraception during work agree to continue to apply their methods those who
- •According to the urodynamic test results, the researcher appropriate to be included in the study by patients with
- •After physical and neurological examination inclusion in the study was made by the researcher. eligible patients
- •Previous response to standard treatments (medication, etc.) non-responders (non-responders to methods such as pelvic floor muscle exercises (with or without physical therapy), behavioral and lifestyle modifications, continence-assisted pessaries, and pharmacotherapy)
Exclusion Criteria
- •Women who are pregnant, supported by biochemical laboratory findings
- •Those in the urinary incontinence category other than SUI
- •Those with significant pelvic organ prolapse (e.g., cystocele, rectocele); (as defined by the International Continence Society greater than phase II)
- •Those with neurological disorders (e.g., multiple sclerosis, Parkinson's disease)
- •Patients with morbid obesity (BMI greater than 40 Those who are)
- •Those with abnormal bladder capacity (more than 300 cc large)
- •Those with abnormal post-void residuals (50 greater than cc)
- •Urethral stricture and bladder neck contracture Those who are
- •Spastic bladder
- •Those with urinary tract infection (UTI)
- •Those with vesicoureteral reflux
- •Those with bladder stones
- •Those with bladder tumors
- •Difficulty understanding and adapting to work is mentally healthy to the extent that it can create patients without
- •Fulfill the requirements of the work plan who may have trouble adapting to bring patients
- •Negative, as determined by the researcher benefit/risk ratio
- •Any research in the previous 30 days treatment (medication or device) has been received.
Outcomes
Primary Outcomes
Urodynamic Assessment
Time Frame: Baseline, 12 months
The bladder is filled using the catheter and pressure measurements are continuously recorded and patient feedback regarding bladder sensation and urgency. Testing for stress incontinence is performed with coughing and straining. Leak Point Pressure and leakage episodes are recorded and analyzed to provide information regarding the type and severity of incontinence. At the end of the test, urine is passed to assess bladder function further and look for blockage of urinary flow.
Twenty-Four-Hour Pad Testing
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months
This test is performed at home. Women are provided with a set of pads and advised not to modify their normal drinking or activities. The aim of such tests is to document leakage in a normal home environment. Pad loss greater than 4 g is designated as significant or a 'positive pad test'.
Evaluation of Quality of Life
Time Frame: Baseline, 6 weeks, 12 months
The Incontinence Quality of Life Scale (I-QOL), consisting of 22 questions, was used to analyze the improvement in quality of life. It is a validated questionnaire. Higher scores indicate a better level of quality of life compared to lower scores.
One-Hour Pad Testing
Time Frame: Baseline, 6 weeks, 3 months, 6 months, 12 months
This test is performed in a clinical setting. They include a filling phase, during which the patient spends 15 minutes drinking 500 ml of fluid. This is followed by a series of provocative maneuvers, such as coughing and jumping, to try to stimulate urinary leakage. Pads are weighed before and at the end of the test. Pad loss ≥ 2 g is designated as significant or a 'positive pad test.
Number of Total Daily Incontinence Episodes
Time Frame: 6 weeks, 3 months, 6 months, 12 months
It was obtained using a three-day bladder diary. Objective. Meaningful for patients. Correlates with patients' daily activities. It may not be directly related to the severity of urine leakage. Subject to variability. Requires patient compliance. Day and night urine leakages were recorded separately by the patient for three days. The mean total score for a day was calculated.
Secondary Outcomes
- Symptomatic Impact Assessment(Baseline, 12 months)
- Assessment of Sexual Function(Baseline, 12 months)
- Post-Voiding Residual (PVR) Urine Volume(Baseline, 12 months)
- Assessment of Serious Adverse Events and Adverse Events(Intraoperative, postoperative 6 weeks, 3 months, 6 months, 12 months)
- Symptomatic Assessment for Overactivitive Bladder(Baseline, 12 months)
- Assess the Impact of the Dysfunction on Quality of Life(Baseline, 12 months)
- Assessment of Sexual Function during Intercourse(Baseline, 12 months)